Goldman Sachs’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.5M | Buy |
106,400
+48,300
| +83% | +$8.9M | ﹤0.01% | 2459 |
|
|
2025
Q4 | $10.2M | Buy |
+58,100
| New | +$9.49M | ﹤0.01% | 3078 |
|
|
2023
Q3 | – | Sell |
-12,000
| Closed | -$3.42M | – | 5546 |
|
|
2023
Q2 | $3.42M | Buy |
12,000
+7,300
| +155% | +$2.17M | ﹤0.01% | 3433 |
|
|
2023
Q1 | $1.31M | Sell |
4,700
-36,900
| -89% | -$10.2M | ﹤0.01% | 4189 |
|
|
2022
Q4 | $11.5M | Sell |
41,600
-10,000
| -19% | -$2.82M | ﹤0.01% | 2450 |
|
|
2022
Q3 | $13.8M | Buy |
51,600
+47,900
| +1,295% | +$10.2M | ﹤0.01% | 2200 |
|
|
2022
Q2 | $755K | Hold |
3,700
| – | – | ﹤0.01% | 4812 |
|
|
2022
Q1 | $779K | Sell |
3,700
-36,300
| -91% | -$7.89M | ﹤0.01% | 5021 |
|
|
2021
Q4 | $9.6M | Sell |
40,000
-15,000
| -27% | -$3.86M | ﹤0.01% | 2811 |
|
|
2021
Q3 | $15.6M | Buy |
55,000
+15,000
| +38% | +$4.92M | ﹤0.01% | 2298 |
|
|
2021
Q2 | $13.9M | Sell |
40,000
-30,000
| -43% | -$9.09M | ﹤0.01% | 2387 |
|
|
2021
Q1 | $19.6M | Sell |
70,000
-50,300
| -42% | -$13.6M | ﹤0.01% | 1943 |
|
|
2020
Q4 | $29.5M | Buy |
120,300
+88,300
| +276% | +$22.8M | 0.01% | 1533 |
|
|
2020
Q3 | $9.08M | Buy |
+32,000
| New | +$8.93M | ﹤0.01% | 2412 |
|
|
2020
Q2 | – | Sell |
-72,700
| Closed | -$23M | – | 5208 |
|
|
2020
Q1 | $23M | Buy |
72,700
+46,400
| +176% | +$14.1M | 0.01% | 1417 |
|
|
2019
Q4 | $7.8M | Sell |
26,300
-3,200
| -11% | -$888K | ﹤0.01% | 2621 |
|
|
2019
Q3 | $6.87M | Buy |
29,500
+20,600
| +231% | +$4.8M | ﹤0.01% | 2617 |
|
|
2019
Q2 | $2.08M | Sell |
8,900
-9,800
| -52% | -$2.26M | ﹤0.01% | 3519 |
|
|
2019
Q1 | $4.42M | Sell |
18,700
-55,300
| -75% | -$17.4M | ﹤0.01% | 3068 |
|
|
2018
Q4 | $22.3M | Sell |
74,000
-10,400
| -12% | -$3.32M | 0.01% | 1719 |
|
|
2018
Q3 | $29.8M | Buy |
84,400
+5,100
| +6% | +$1.76M | 0.01% | 1616 |
|
|
2018
Q2 | $23M | Sell |
79,300
-17,400
| -18% | -$4.89M | 0.01% | 1771 |
|
|
2018
Q1 | $26.5M | Buy |
96,700
+27,100
| +39% | +$8.41M | 0.01% | 1621 |
|
|
2017
Q4 | $22.2M | Sell |
69,600
-14,700
| -17% | -$4.72M | 0.01% | 1862 |
|
|
2017
Q3 | $26.4M | Buy |
84,300
+20,100
| +31% | +$5.95M | 0.01% | 1773 |
|
|
2017
Q2 | $17.4M | Buy |
64,200
+18,700
| +41% | +$4.94M | ﹤0.01% | 2042 |
|
|
2017
Q1 | $12.4M | Sell |
45,500
-52,300
| -53% | -$14.8M | ﹤0.01% | 2243 |
|
|
2016
Q4 | $27.7M | Sell |
97,800
-12,400
| -11% | -$3.68M | 0.01% | 1727 |
|
|
2016
Q3 | $34.5M | Buy |
110,200
+32,700
| +42% | +$9.68M | 0.01% | 1487 |
|
|
2016
Q2 | $18.7M | Sell |
77,500
-50,700
| -40% | -$13.4M | 0.01% | 1834 |
|
|
2016
Q1 | $33.4M | Sell |
128,200
-232,100
| -64% | -$61.3M | 0.01% | 1354 |
|
|
2015
Q4 | $110M | Sell |
360,300
-81,800
| -19% | -$23.5M | 0.03% | 621 |
|
|
2015
Q3 | $129M | Buy |
442,100
+240,800
| +120% | +$79.5M | 0.04% | 492 |
|
|
2015
Q2 | $81.3M | Buy |
201,300
+55,800
| +38% | +$22.4M | 0.03% | 794 |
|
|
2015
Q1 | $61.4M | Buy |
145,500
+52,100
| +56% | +$20.5M | 0.02% | 945 |
|
|
2014
Q4 | $31.7M | Sell |
93,400
-6,900
| -7% | -$2.23M | 0.01% | 1477 |
|
|
2014
Q3 | $33.2M | Buy |
100,300
+10,700
| +12% | +$3.53M | 0.01% | 1403 |
|
|
2014
Q2 | $28.3M | Sell |
89,600
-20,500
| -19% | -$6.17M | 0.01% | 1525 |
|
|
2014
Q1 | $33.7M | Sell |
110,100
-5,900
| -5% | -$1.87M | 0.01% | 1343 |
|
|
2013
Q4 | $32.4M | Buy |
116,000
+34,900
| +43% | +$9.03M | 0.01% | 1385 |
|
|
2013
Q3 | $19.5M | Buy |
81,100
+3,100
| +4% | +$694K | 0.01% | 1646 |
|
|
2013
Q2 | $16.8M | Buy |
+78,000
| New | +$16.7M | 0.01% | 1662 |
|
Other funds holding BIIB
VCM
VPM
Goldman Sachs's BIIB Position: Q1 2026 in Review
Goldman Sachs reduced its Biogen (BIIB) stake by 4.4% in Q1 2026, selling an estimated $8.89M and leaving 1,051,094 shares worth $193M. The position accounts for 0.02% of the portfolio, ranked #691.
Goldman Sachs first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $800M in Q3 2018. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Goldman Sachs held 1,051,094 shares of Biogen worth $193M as of Q1 2026.
- Goldman Sachs sold 48,272 Biogen shares in Q1 2026, an estimated $8.89M.
- Biogen made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #691 holding.
- Goldman Sachs first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Goldman Sachs's Biogen position peaked at $800M in Q3 2018.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.